Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12

F. Heitz; P. Harter; E. Åvail-Lundqvist; A. Reuss; P. Pautier; G. Cormio; N. Colombo; A. Reinthaller; I. Vergote; A. Poveda; P. B. Ottevanger; L. C. Hanker; A. Leminen; J. Alexandre; U. Canzler; J. Sehouli; J. Herrstedt; B. Fiane; M. Merger; A. du Bois

doi:10.1016/j.ygyno.2018.11.008

Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12

F. Heitz, P. Harter, E. Åvail-Lundqvist, A. Reuss, P. Pautier, G. Cormio, N. Colombo, A. Reinthaller, I. Vergote, A. Poveda, P. B. Ottevanger, L. C. Hanker, A. Leminen, J. Alexandre, U. Canzler, J. Sehouli, J. Herrstedt, B. Fiane, M. Merger, A. du Bois

Tutkimustuotos: Artikkelijulkaisu › Artikkeli › Tieteellinen › vertaisarvioitu

Alkuperäiskieli	englanti
Lehti	Gynecologic Oncology
Vuosikerta	152
Numero	2
Sivut	235-242
Sivumäärä	8
ISSN	0090-8258
DOI - pysyväislinkit	https://doi.org/10.1016/j.ygyno.2018.11.008
Tila	Julkaistu - helmik. 2019
OKM-julkaisutyyppi	A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu

Tieteenalat

3123 Naisten- ja lastentaudit

Pääsy asiakirjaan

10.1016/j.ygyno.2018.11.008

Siteeraa tätä

Heitz, F., Harter, P., Åvail-Lundqvist, E., Reuss, A., Pautier, P., Cormio, G., Colombo, N., Reinthaller, A., Vergote, I., Poveda, A., Ottevanger, P. B., Hanker, L. C., Leminen, A., Alexandre, J., Canzler, U., Sehouli, J., Herrstedt, J., Fiane, B., Merger, M., & du Bois, A. (2019). Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12. Gynecologic Oncology, 152(2), 235-242. https://doi.org/10.1016/j.ygyno.2018.11.008

@article{6aa50fb0e5fc42c7b983ef83e0f2abef,

title = "Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12",

keywords = "Advanced ovarian cancer, Debulking surgery, Pre-chemotherapy imaging, Prognosis, EPITHELIAL OVARIAN, CYTOREDUCTIVE SURGERY, COMPUTED-TOMOGRAPHY, POSTOPERATIVE CT, CHEMOTHERAPY, BEVACIZUMAB, CARCINOMA, INITIATION, INTERVAL, THERAPY, 3123 Gynaecology and paediatrics",

author = "F. Heitz and P. Harter and E. {\AA}vail-Lundqvist and A. Reuss and P. Pautier and G. Cormio and N. Colombo and A. Reinthaller and I. Vergote and A. Poveda and Ottevanger, {P. B.} and Hanker, {L. C.} and A. Leminen and J. Alexandre and U. Canzler and J. Sehouli and J. Herrstedt and B. Fiane and M. Merger and {du Bois}, A.",

year = "2019",

month = feb,

doi = "10.1016/j.ygyno.2018.11.008",

language = "English",

volume = "152",

pages = "235--242",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "ACADEMIC PRESS INC ELSEVIER SCIENCE",

number = "2",

}

Heitz, F, Harter, P, Åvail-Lundqvist, E, Reuss, A, Pautier, P, Cormio, G, Colombo, N, Reinthaller, A, Vergote, I, Poveda, A, Ottevanger, PB, Hanker, LC, Leminen, A, Alexandre, J, Canzler, U, Sehouli, J, Herrstedt, J, Fiane, B, Merger, M & du Bois, A 2019, 'Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12', Gynecologic Oncology, Vuosikerta 152, Nro 2, Sivut 235-242. https://doi.org/10.1016/j.ygyno.2018.11.008

Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12. / Heitz, F.; Harter, P.; Åvail-Lundqvist, E. et al.

julkaisussa: Gynecologic Oncology, Vuosikerta 152, Nro 2, 02.2019, s. 235-242.

Tutkimustuotos: Artikkelijulkaisu › Artikkeli › Tieteellinen › vertaisarvioitu

TY - JOUR

T1 - Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12

AU - Heitz, F.

AU - Harter, P.

AU - Åvail-Lundqvist, E.

AU - Reuss, A.

AU - Pautier, P.

AU - Cormio, G.

AU - Colombo, N.

AU - Reinthaller, A.

AU - Vergote, I.

AU - Poveda, A.

AU - Ottevanger, P. B.

AU - Hanker, L. C.

AU - Leminen, A.

AU - Alexandre, J.

AU - Canzler, U.

AU - Sehouli, J.

AU - Herrstedt, J.

AU - Fiane, B.

AU - Merger, M.

AU - du Bois, A.

PY - 2019/2

Y1 - 2019/2

KW - Advanced ovarian cancer

KW - Debulking surgery

KW - Pre-chemotherapy imaging

KW - Prognosis

KW - EPITHELIAL OVARIAN

KW - CYTOREDUCTIVE SURGERY

KW - COMPUTED-TOMOGRAPHY

KW - POSTOPERATIVE CT

KW - CHEMOTHERAPY

KW - BEVACIZUMAB

KW - CARCINOMA

KW - INITIATION

KW - INTERVAL

KW - THERAPY

KW - 3123 Gynaecology and paediatrics

U2 - 10.1016/j.ygyno.2018.11.008

DO - 10.1016/j.ygyno.2018.11.008

M3 - Article

VL - 152

SP - 235

EP - 242

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -